A randomised controlled trial of long NY-ESO-1 peptide-pulsed autologous dendritic cells with or without alpha-galactosylceramide in high-risk melanoma

Overview of attention for article published in Cancer Immunology, Immunotherapy, March 2023

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (55th percentile)
Good Attention Score compared to outputs of the same age and source (71st percentile)

Mentioned by

twitter: 6 X users

Readers on

mendeley: 23 Mendeley

So far, Altmetric has seen 7 X posts from 6 X users, with an upper bound of 47,857 followers.

Activating NKT cells with alpha gal ceramide does not increase potency of NY-ESO-1 peptide vaccine to #Cancer https://t.co/zskJMq7dV4

RT @BrimbleM: Wonderful to see this great team effort!! Thanks for including us.

RT @Ferrier_Inst: "A randomised controlled trial of long NY-ESO-1 peptide-pulsed autologous dendritic cells with or without alpha-galactosy…

Wonderful to see this great team effort!! Thanks for including us.

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 3 additional X posts.